Terns Pharmaceuticals, Inc. (TERN, Financial) experienced a notable stock price increase of 5.10%, reaching $6.18 per share. The trading volume hit 1.23112 million shares, with a turnover rate of 1.45% and a price fluctuation of 5.95%. Despite recent financial reports showing zero revenue and a net loss of $21.95 million, with an earnings per share (EPS) of -$0.28 and a gross profit of -$206,000, the stock maintains a price-to-earnings (P/E) ratio of -5.23.
Analyst ratings reveal a strong market sentiment towards Terns Pharmaceuticals, with 78% of the nine participating institutions recommending a buy and 22% suggesting a hold, while no institution advised selling. This reflects optimism in the company's potential despite current financial setbacks.
Within the biotechnology sector, which saw an overall increase of 0.45%, Terns Pharmaceuticals stood out. Other significant movers in the sector included Neurosense Therapeutics Ltd, Protagenic Therapeutics Inc, and Rocket Pharmaceuticals Inc, which recorded substantial gains. Active stocks with high turnover rates included Cyclerion Therapeutics, Inc., Outlook Therapeutics, Inc., and Tc Biopharm (Holdings) Plc. Stocks with notable price fluctuations were Neurosense Therapeutics Ltd, Silexion Therapeutics Corp, and Protagenic Therapeutics Inc.
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing small molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases.
